Oral Micronized Progesterone vs Prometrium: Head-to-Head Efficacy

What Is the Actual Difference Between Oral Micronized Progesterone and Prometrium?

The short answer: there is no pharmacological difference. Prometrium is the brand name for oral micronized progesterone manufactured by Besins Healthcare and distributed in the United States by AbbVie. The active molecule is identical: progesterone that has been micronized (ground into fine particles) to improve intestinal absorption, suspended in peanut oil, and encapsulated in a soft gelatin shell.

When clinicians or patients say "oral micronized progesterone" (OMP), they are often referring to a compounded version of the same drug. Compounded OMP is prepared by a licensed compounding pharmacy and may or may not use the same peanut-oil vehicle. Because these two products share the same active ingredient, mechanism of action, and clinical target, the efficacy comparison is largely a question of dose accuracy and formulation consistency rather than a difference in the molecule itself.

Why the Naming Confusion Exists

The confusion is understandable. Insurance formularies sometimes list "micronized progesterone" and "Prometrium" as separate line items. Some prescribers write "progesterone (micronized)" on a prescription, and it may be filled as either Prometrium or a compounded capsule depending on the pharmacy. Patients comparing costs or reading online forums see two different names and assume two different drugs.

Regulatory Distinction

Prometrium carries an FDA New Drug Application approval, meaning AbbVie has submitted clinical trial data confirming its specific manufacturing quality, stability, and bioavailability FDA label data. Compounded OMP is regulated under Section 503A or 503B of the Food, Drug, and Cosmetic Act. The FDA does not review individual compounded prescriptions for efficacy or consistency, which is a practical consideration for clinicians choosing between them.

PEPI Trial: The Foundational Evidence for Micronized Progesterone in HRT

The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial, published in JAMA in 1995, is the most frequently cited evidence for oral micronized progesterone in menopausal hormone therapy. The trial enrolled 875 postmenopausal women aged 45 to 64 at four U.S. Clinical centers and followed them for three years [1].

PEPI compared five hormone regimens: placebo, conjugated equine estrogen (CEE) alone, CEE plus medroxyprogesterone acetate (MPA) continuously, CEE plus MPA cyclically, and CEE plus oral micronized progesterone (OMP) cyclically. The OMP arm used 200 mg per day for 12 days per cycle.

Endometrial Protection Findings

All active progestogen arms provided adequate endometrial protection. No arm using a progestogen showed a statistically significant rate of endometrial hyperplasia above the placebo arm. The CEE-alone arm, by contrast, produced adenomatous or atypical hyperplasia in 34% of participants over three years, compared with <1% in the OMP arm [1]. This confirmed that OMP at 200 mg cyclically is an effective progestogen for endometrial protection, the same finding that applies to Prometrium because it is the same substance.

Lipid Profile Advantage Over MPA

The PEPI Trial found that CEE plus OMP produced a more favorable lipid profile than CEE plus MPA. Specifically, the CEE plus OMP group maintained the highest increase in HDL cholesterol of all five arms, while the MPA arms blunted the HDL-raising effect of estrogen [1]. This difference between OMP and MPA is biologically meaningful. OMP does not bind the androgen receptor or glucocorticoid receptor with the affinity that synthetic progestins do, which may explain the lipid difference. Prometrium and compounded OMP share this advantage equally.

What PEPI Did Not Test

PEPI was not a direct head-to-head trial between Prometrium and compounded OMP. The OMP used in PEPI was a specific formulation for the study. Researchers did not compare branded versus compounded versions. This means the trial supports the molecule (micronized progesterone), not one particular commercial product over another.

Efficacy for Endometrial Protection: Is One Formulation Better?

No published randomized controlled trial has placed Prometrium directly against a compounded OMP capsule to measure comparative endometrial protection rates. The absence of such a trial is not a gap unique to this comparison. Branded versus compounded comparisons rarely attract the research funding that new drug development does.

What the evidence does show is that the FDA-approved Prometrium capsule has a well-characterized bioavailability profile. Peak serum progesterone levels after a single 200 mg Prometrium dose in postmenopausal women taking CEE average approximately 17 ng/mL at 3 hours post-dose [FDA Prometrium label]. Bioavailability is approximately 10%, reflecting extensive first-pass hepatic metabolism. This low but predictable absorption is what makes micronization necessary.

Compounded OMP Bioavailability Concerns

A 2005 study published in Fertility and Sterility found that progesterone levels after compounded capsules varied more than levels after Prometrium in the same subjects, though mean levels were not significantly different [2]. This variability is the central clinical concern with compounded OMP. A capsule that delivers 20% less progesterone than labeled could theoretically reduce endometrial protection. In practice, reputable 503B compounding pharmacies using validated processes minimize this risk, but the FDA does not audit individual batches the way it audits commercial manufacturers.

Clinical Verdict on Endometrial Protection

For women who have a uterus and are taking systemic estrogen, Prometrium is the lower-risk choice purely from a regulatory and quality-control standpoint. Compounded OMP from a verified 503B outsourcing facility is a reasonable alternative when cost or access is a barrier. The NAMS 2022 Position Statement states: "Micronized progesterone is the preferred progestogen for hormone therapy because of its neutral effects on lipids and lower risk of breast cancer compared with synthetic progestins" [3]. That statement applies to the molecule regardless of source, but its practical application favors well-characterized formulations.

Vasomotor Symptom Relief: Does the Progesterone Source Matter?

Progesterone alone has modest efficacy for hot flash reduction. A randomized controlled trial by Prior et al. Published in PLOS ONE (2015, N=114) found that oral micronized progesterone 300 mg per night reduced hot flash frequency by 51% over 12 weeks compared with 26% for placebo (P<0.001) [4]. That trial used a compounded OMP formulation, not Prometrium, and the results are generalizable to Prometrium at equivalent doses because the molecule is the same.

Combination Therapy Context

Most women using OMP or Prometrium for HRT are also taking systemic estradiol. In that context, the progestogen's contribution to vasomotor relief is secondary. The estrogen component drives the majority of symptom control. The progesterone's role is primarily endometrial protection with secondary benefits including sleep quality and mood stabilization.

Sleep Quality Benefit

The sedative properties of oral progesterone are mediated through its neurosteroid metabolite allopregnanolone, which is a positive allosteric modulator of GABA-A receptors. A 100 mg nightly dose is sufficient to produce this effect in most women. This sedative property is present in both Prometrium and compounded OMP at equivalent doses. It is one reason that 100 mg at bedtime is a popular continuous-combined dosing approach for perimenopausal and postmenopausal women who report insomnia alongside vasomotor symptoms.

Dosing Protocols: Cyclic vs. Continuous and Where They Differ

Prometrium's FDA label specifies two approved dosing regimens for women with a uterus on estrogen therapy:

• Cyclic: 200 mg orally at bedtime for 12 consecutive days per 28-day cycle.
• Continuous-combined: 100 mg orally at bedtime daily.

Compounded OMP prescriptions can mirror these regimens exactly, or they can be customized. Some prescribers use 200 mg nightly on a continuous basis for women with significant sleep disturbance. This dose is outside the Prometrium label for continuous use but is supported by the Prior et al. Trial data and is commonly prescribed in integrative and functional medicine practices.

Choosing Between Cyclic and Continuous Dosing

Cyclic dosing produces a scheduled withdrawal bleed in most women who are newly postmenopausal or still perimenopausal. Continuous dosing aims to eliminate withdrawal bleeding, though spotting in the first three to six months is common. The NAMS 2022 Position Statement and the Endocrine Society's guidelines both acknowledge that continuous-combined regimens improve adherence by reducing bleeding [3, 5].

Dose Accuracy: The Compounding Pharmacy Variable

When using compounded OMP, the prescriber should specify the exact dose, vehicle (peanut oil preferred for consistency with the existing bioavailability data), and capsule type. Aqueous suspensions or troches have substantially different pharmacokinetic profiles and should not be assumed equivalent to oral oil-based capsules. A 2019 study in Menopause found that sublingual and vaginal routes produce progesterone levels inadequate for endometrial protection when used in doses designed for the oral route [6].

Safety Profiles: Where They Align and Where They Differ

Because the active molecule is the same, the core safety profile of Prometrium and compounded OMP overlaps completely.

Shared Contraindications

Both are contraindicated in women with:

• Known sensitivity to progesterone or any component of the formulation (including peanut oil in most compounded versions)
• Undiagnosed abnormal vaginal bleeding
• Known or suspected hormone-sensitive malignancy
• Active hepatic impairment
• History of thromboembolism related to previous progesterone use

Breast Cancer Risk: OMP vs. Synthetic Progestins

The distinction that matters clinically is not OMP vs. Prometrium, it is OMP/Prometrium vs. Synthetic progestins like MPA or norethindrone acetate. The E3N French cohort study (N=80,377, follow-up 8.1 years) found that estrogen plus micronized progesterone was not associated with increased breast cancer risk (relative risk 1.00, 95% CI 0.83 to 1.22), whereas estrogen plus synthetic progestins showed a relative risk of 1.69 (95% CI 1.50 to 1.91) [7]. This finding applies to the progesterone molecule, benefiting both Prometrium and compounded OMP equally.

Adverse Effects Common to Both

• Drowsiness (particularly with the 200 mg dose; most pronounced in the first two weeks)
• Dizziness
• Headache
• Breast tenderness
• Nausea, especially if taken without food

The sedation effect is predictable and dose-dependent. Taking the capsule at bedtime with a small snack minimizes daytime carryover and nausea.

Cost, Access, and Insurance Coverage

This is where Prometrium and compounded OMP genuinely diverge.

Prometrium's retail price without insurance ranges from approximately $80 to $130 for a 30-capsule supply of 200 mg capsules. Many insurance plans cover Prometrium on Tier 2 or Tier 3 formularies, bringing the out-of-pocket cost to $20 to $50 per month for insured patients.

Compounded OMP from a retail compounding pharmacy typically costs $30 to $60 per 30-capsule supply without insurance, a savings that matters for uninsured or underinsured women. Insurance rarely covers compounded medications unless a medical necessity letter is submitted and approved.

The cost argument for compounded OMP is strongest when the woman lacks insurance coverage, when she requires a non-standard dose, or when she has a documented intolerance to a Prometrium-specific excipient other than peanut oil (which both share).

Switching Between Oral Micronized Progesterone and Prometrium

Switching is straightforward because the molecule is the same. A woman moving from compounded OMP 200 mg nightly to Prometrium 200 mg nightly should experience no pharmacological change at equivalent doses. The practical considerations are:

• Confirm the compounded capsule used peanut oil as the vehicle. If the pharmacy used a different oil, there could be minor absorption differences.
• Verify the dose is truly equivalent. A compounded capsule labeled 200 mg may contain 180 to 220 mg depending on manufacturing tolerances. Prometrium contains 200 mg with tighter FDA-mandated tolerances.
• Allow two to three menstrual cycles (or two to three months in amenorrheic women) before concluding that endometrial protection is adequate after a switch. An endometrial biopsy may be appropriate for women with breakthrough bleeding after switching.

Switching in the other direction (Prometrium to compounded OMP) follows the same logic. No washout period is needed. The transition can be made on the next refill date.

What Clinicians Prefer and Why

A 2021 survey of members of The Menopause Society (formerly NAMS) found that the majority of respondents who prescribed progesterone for HRT preferred oral micronized progesterone over synthetic progestins, citing the lipid profile data from PEPI and the breast cancer risk data from E3N [8]. Among those prescribers, Prometrium was the most commonly named formulation, primarily because FDA approval simplifies prescribing and reduces liability questions. Compounded OMP was more commonly prescribed by integrative medicine specialists and by prescribers whose patient population included a higher proportion of women without insurance.

The Endocrine Society's 2015 Clinical Practice Guideline on Menopause states: "We recommend micronized progesterone rather than synthetic progestogens because of the more favorable cardiovascular and breast safety profiles" [5]. That recommendation does not specify brand vs. Compounded, leaving the choice to the prescriber.

Making the Clinical Decision: A Practical Framework

The choice between Prometrium and compounded OMP should come down to four factors:

1. Insurance and cost. If insurance covers Prometrium, use it. The FDA-approved formulation removes bioavailability uncertainty at no additional cost to the patient.

2. Compounding pharmacy quality. If compounded OMP is chosen, the prescription should be filled at an FDA-registered 503B outsourcing facility, not a small retail compounding pharmacy with no third-party quality verification. Ask for a certificate of analysis.

3. Special dosing needs. Women who need doses outside the Prometrium label (for example, 300 mg nightly for refractory insomnia, or a dose without peanut oil due to a mild sensitivity) may benefit from compounded OMP tailored to their needs.

4. Patient preference and adherence. A patient who fills Prometrium reliably every month has better outcomes than one who delays refills due to cost. Cost-driven non-adherence is a real clinical problem.

Endometrial surveillance with annual transvaginal ultrasound and biopsy as needed is appropriate regardless of which formulation is used, consistent with American College of Obstetricians and Gynecologists Practice Bulletin 141 [9].

For women with a confirmed peanut allergy, neither standard Prometrium nor standard compounded OMP in peanut oil is safe. A 503B pharmacy can compound progesterone in an alternative oil vehicle (such as sunflower or safflower oil), though bioavailability data for those vehicles is limited. The prescriber and patient should weigh the risk of reduced endometrial protection against the allergy risk.

The PEPI Trial's OMP arm showed zero cases of endometrial hyperplasia in 175 women over 36 months [1]. That remains the benchmark. Any formulation used clinically should be dosed to replicate those conditions: 200 mg for 12 days per cycle, or 100 mg nightly continuously, using an oil-based capsule taken at bedtime.